HOME >> BIOLOGY >> NEWS
Joslin Diabetes Center study examines insulin pump therapy in adolescents

BOSTON -- October 31, 2006 -- In spite of its many advantages, there are many challenges to using an insulin pump to treat type 1 diabetes. Despite these challenges, however, more and more youngsters are choosing pump therapy, even though important questions remain about the pump's effectiveness for this age group: With all its risks and demands, is it a method of treatment that children and teens can maintain? What causes adolescents to go off of pump therapy and how often does this occur? Is it possible to identify those youth unable to meet the demands of pump therapy and to find interventions that will help them succeed?

Now, in the first long-term investigation conducted among pediatric patients who chose to go on pump therapy (rather than using it as part of a clinical trial), a new study in the November issue of Diabetes Care by researchers in the Pediatric, Adolescent, and Young Adult Section at Joslin Diabetes Center, is providing answers. Following a group of 161 children and adolescents, ages 4-21, for an average of four years, the researchers have shown that with proper training and follow-up, for the great majority of patients--more than 80 percent of the children in this study--insulin pump therapy provides a lasting and effective mode of treatment. They also identified several factors that put patients at risk for failure in adapting to pump use.

"More than 130 patients were able to use the pump effectively," says senior author, Lori Laffel, M.D., M.P.H., Chief of Joslin's Pediatric, Adolescent and Young Adult Section, an Investigator in the Genetics and Epidemiology Section and Associate Professor of Pediatrics at Harvard Medical School. "By looking at differences between the patients who remained on pump therapy and those who returned to injected insulin, we were able to identify factors present even at the start of pump therapy that were predictive of failure. For example, patients who resumed injection therapy checked their b
'"/>

Contact: Jenny Eriksen
jenny.eriksen@joslin.harvard.edu
617-732-2415
Joslin Diabetes Center
31-Oct-2006


Page: 1 2 3 4

Related biology news :

1. Joslin study indicates insulin receptors play a critical role in promoting islet growth
2. Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects
3. Joslin study reveals how a specific fat type can protect against weight gain and diabetes
4. Joslin discovers protein that causes blood vessel leakage and swelling with diabetic retinopathy
5. Joslin-led study uncovers role of appetite hormone MCH in insulin production
6. Joslin Diabetes Center in Boston establishes first affiliate in Canada
7. Walgreens and Joslin Diabetes Center form broad alliance to improve diabetes outcomes
8. Joslin awards Victory Medal to New York man living 75 years with type 1 diabetes
9. Joslins new book demystifies nutrition and meal planning for people with diabetes
10. Joslin study refutes recent report that bone marrow can replenish female oocytes
11. Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... Catalent, the leading ... cell and gene therapies, and consumer health products, today announced that two Catalent ... & Expo, taking place between Aug. 31 – September 4, 2020. , On ...
(Date:8/23/2020)... WOODLANDS, Texas (PRWEB) , ... August 21, 2020 ... ... from Rigaku Corporation has been published and is now available on ... single crystal X-ray diffraction—serves the X-ray analysis community, presenting current news and crystallographic ...
(Date:8/21/2020)... ... August 19, 2020 , ... “How can ... businesses dedicated to Salivary Bioscience for more than twenty years. Together with Douglas ... Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research and Applications ," and ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... (PRWEB) , ... August 11, 2020 , ... ... a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network ... 2021 and 2022. The network is a consortium of academic research centers in ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics ... , Known as MediVet Biologics since its formation in 2016, the company ... Ardent Animal Health will build on its base of innovative therapies for osteoarthritis and ...
(Date:7/31/2020)... SOMERSET, N.J (PRWEB) , ... July 29, 2020 ... ... editing company, and Catalent, the leading global provider of advanced delivery technologies, development, ... products, today announced that they have entered into a strategic partnership whereby Catalent ...
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter maintenance and ... successful study, while protecting and accessing the catheter or device post-surgery is often undervalued ... Envigo in a live webinar on Wednesday, August 5, 2020 at ...
Breaking Biology Technology:
Cached News: